Table 2B.
Factors | ABA | ZT | GA1 | |
---|---|---|---|---|
ng g−1 FW | ng g−1 FW | ng g−1 FW | ||
Treatment (T) | Control | 98.5a | 16.1c | 0.49c |
60 mgL−1 BAP | 91.1c | 16.8b | 0.57a | |
20 mgL−1 GA3 | 95.2b | 16.3c | 0.53b | |
60 mgL−1 BAP + 20 mgL−1 GA3 | 89.9c | 17.0a | 0.57a | |
LSD T (P ≤ 0.05) | 1.25 | 0.22 | 0.026 | |
Genotype (G) | FD51-5 | 60.4e | 19.4b | 0.63b |
PRI red | 53.3f | 22.8a | 0.71a | |
Sante | 99.0c | 14.4d | 0.46d | |
FD73-49 | 94.3d | 17.4c | 0.51c | |
FD69-1 | 120.5b | 12.8e | 0.48cd | |
FD8-1 | 134.6a | 12.5f | 0.43e | |
LSD G (P ≤ 0.05) | 1.53 | 0.27 | 0.032 | |
Storage period (SP) | 1 Week | 124.9a | 9.8a | 0.58a |
3 Week | 62.3b | 23.3b | 0.49b | |
LSD SP (P ≤ 0.05) | 0.89 | 0.16 | 0.019 | |
LSD T × G (P ≤ 0.05) | NS | NS | NS | |
LSD T × SP (P ≤ 0.05) | NS | NS | NS | |
LSD G × SP (P ≤ 0.05) | 2.17 | 0.39 | 0.046 | |
LSD T × G × SP (P ≤ 0.05) | NS | NS | NS |
NS, non-significant at P ≤ 0.05.
Treatment means sharing same letter differ non-significantly.
ABA, abscisic acid; GA1, gibberellin A1; BAP, benzylaminopurine; GA3, gibberellic acid; LSD, least significant difference.